StockNews.com Begins Coverage on Curis (NASDAQ:CRIS)

StockNews.com began coverage on shares of Curis (NASDAQ:CRIS) in a report issued on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright decreased their price objective on Curis from $20.00 to $16.00 and set a “buy” rating on the stock in a report on Monday, March 31st.

Curis Stock Performance

CRIS opened at $1.89 on Thursday. The company has a fifty day moving average of $2.00 and a two-hundred day moving average of $3.07. The stock has a market capitalization of $16.04 million, a price-to-earnings ratio of -0.24 and a beta of 3.65. Curis has a fifty-two week low of $1.02 and a fifty-two week high of $16.80.

Curis (NASDAQ:CRIS) last announced its earnings results on Tuesday, May 6th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.14) by ($0.11). The business had revenue of $2.38 million for the quarter, compared to analysts’ expectations of $2.37 million. Curis had a negative net margin of 443.35% and a negative return on equity of 923.37%. During the same quarter last year, the business earned ($2.05) EPS. On average, equities research analysts forecast that Curis will post -7.12 earnings per share for the current year.

Hedge Funds Weigh In On Curis

Several hedge funds have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in shares of Curis in the first quarter valued at approximately $27,000. Squarepoint Ops LLC acquired a new position in shares of Curis in the fourth quarter worth $35,000. Millennium Management LLC increased its position in shares of Curis by 92.6% during the fourth quarter. Millennium Management LLC now owns 25,557 shares of the biotechnology company’s stock worth $78,000 after acquiring an additional 12,287 shares during the period. Focused Wealth Management Inc raised its stake in shares of Curis by 9.5% in the fourth quarter. Focused Wealth Management Inc now owns 59,204 shares of the biotechnology company’s stock valued at $181,000 after acquiring an additional 5,138 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Curis by 27.3% in the fourth quarter. Geode Capital Management LLC now owns 83,129 shares of the biotechnology company’s stock valued at $254,000 after purchasing an additional 17,820 shares during the period. Institutional investors and hedge funds own 29.97% of the company’s stock.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.